No Data
No Data
Meinong Biotech (301156.SZ): It has now established a sales network in Brazil and other countries and regions
Gelonghui, May 14, 丨 Meinong Biotech (301156.SZ) recently said during a survey reception from institutional investors that the company has always been committed to exploring and developing the international market, and has laid a good foundation for the international market for more than 20 years. At present, the company has established sales networks in various countries and regions such as Vietnam, Russia, Thailand, Myanmar, the Philippines, Japan, South Korea, Pakistan, Bangladesh, Egypt, Jordan, Turkey, and Brazil. The company's future development plan for overseas business: (1) Following the country's “Belt and Road” policy, the company will focus on developing the Southeast Asian market, South Asia and the Middle East market. (2) At
Express News | Meinong Biotech invests in the establishment of an animal nutrition technology company
Express News | Meinong Biotech: The company's recent production and operation situation and internal and external business environment have not occurred or are expected to change significantly
Meinong Biotech (301156.SZ) plans to transfer 10 shares to 3 shares and distribute 5.5 yuan, excluding interest on May 13
Meinong Biotech (301156.SZ) announced that the company's 2023 equity distribution plan: 5.5 yuan (tax included) for every 10 shares to all shareholders; at the same time, the capital reserve fund will be used to transfer 3 shares for every 10 shares to all shareholders. The ex-dividend date is May 13, 2024.
Haili Wind Power (301156): Performance is under phased pressure, and the inflection point of the sea landscape recovery is imminent
Incident Company's 2023 Annual Report: The company's revenue in 2023 was 1,685 billion yuan, up 3.22% year on year; net profit loss to mother was 88 million yuan, down 143.0% year on year. The company's 2024 quarterly report:
Meinong Biotech (301156.SZ): Net profit of 9.58 million yuan in the first quarter increased 0.47% year-on-year
On April 24, Gelonghui Biotech (301156.SZ) released its first quarter report. Operating revenue was 97.906 million yuan, up 7.57% year on year, net profit of 9.58 million yuan, up 0.47% year on year, after deducting non-net profit of 8.979 million yuan, down 2.49% year on year, with basic earnings of 0.0856 yuan per share.
No Data